Barclays has downgraded three prominent European consumer ingredients stocks and trimmed profit forecasts for the group, citing a new wave of energy-driven inflation tied to the Middle East conflict that will defer the volume recovery investors were expecting in 2026.
The bank moved Givaudan from Overweight to Equal Weight, cut Barry Callebaut from Equal Weight to Underweight, and shifted Corbion to Equal Weight from Overweight. In addition, Barclays reduced price targets across most names it covers in the sector.
Across its coverage, Barclays lowered 2026 EBITDA forecasts by between 2% and 7%, with the largest downgrades affecting Givaudan, Symrise and Barry Callebaut. The analysts used a base-case scenario of oil at $85 per barrel and European gas at €45/MWh for 2026 when modelling the impact.
Under that scenario, Barclays estimates companies will need to implement roughly 3% of incremental pricing in the second half of 2026 to compensate for pressure on gross profit. Fragrance-focused firms such as Givaudan and Symrise are seen as facing the steepest pricing requirements because they rely more heavily on oil-linked raw materials.
Barclays raised its 2026 pricing assumptions across the group by 1-3%, while cutting expected volumes by 1-3%. The bank argued that customers will prioritise protecting margins rather than pursuing innovation, which pushes out the demand rebound that had been anticipated.
"Pricing power should hold, but volume - not cost - is the key concern," the analysts led by Alex Sloane wrote in their note.
Givaudan under the most pressure
The analysts painted the case against Givaudan as the most acute. They highlighted the company’s high exposure to oil-linked inputs and noted it has the largest Middle East exposure in the group, where Fine Fragrance has been a major growth driver. Barclays also pointed to ongoing underperformance in Givaudan’s Taste & Wellbeing division.
Barclays warned of a potential Q2 "air pocket" as Middle East disruption filters through to orders with a lag. At the same time, Givaudan’s valuation remains at a premium to peers, which Barclays said looks increasingly difficult to justify under the new outlook. The price target for Givaudan was lowered to CHF 3,050 from CHF 3,550.
Barry Callebaut and working capital sensitivity
Barry Callebaut was downgraded on the basis that its recent strong rerating leaves little room for error. The analysts noted the company's sensitivity to cocoa prices, saying each £100 per tonne move in cocoa translates into a 70-80 million Swiss franc working-capital impact.
Barclays also flagged the new CEO’s mandate to restore competitiveness, which could increase the likelihood of reinvestment that might cap the near-term EBIT recovery. The analysts said such reinvestment may be sensible for the longer-term health of the business but raises the prospect of downgrades in the near term.
Corbion’s volume-dependent outlook
Corbion was downgraded as Barclays views its volume-dependent recovery as increasingly stretched. The upside case for Corbion relies on a step-up in volumes for Food Ingredients & Solutions, yet with customers expected to prioritise margin protection over innovation, the analysts see that volume improvement as unlikely to materialise in 2026.
Relative preference: Novonesis
Despite the broader downgrades, Barclays kept Novonesis as its preferred pick in the group, retaining an Overweight rating. The bank cited structural demand in dairy and protein, enzyme solutions that help reduce customer costs, and relatively strong pricing power as reasons Novonesis should be more resilient in a more inflationary environment.
The analysts reiterated that relative resilience in areas such as dairy/protein and enzyme-based cost-reduction solutions supports Novonesis’s standing in the current backdrop.
Barclays’ action represents a recalibration of expectations for a sector whose near-term recovery looks more dependent on the timing of energy markets and customers’ willingness to prioritise innovation over margins. The bank’s modelling and the changed ratings underline the challenge companies face in converting pricing power into volume recovery while managing input-cost swings and working-capital impacts.